Galafilgo schreef op 10 maart 2020 20:42:
By Michael Dabaie
Gilead Sciences Inc. unveiled results from a Phase 1b trial evaluating its vesatolimod as part of a human immunodeficiency virus cure research program.
These findings mark the first clinical data showing toll-like receptor 7 stimulation by vesatolimod is associated with a modestly increased time to viral rebound compared to placebo, as well as enhanced immune function and decreased levels of intact HIV DNA, Gilead said.
"The effects are modest, and no one came close to any definition of a cure, but the data suggests real progress might be made when the drug is used in combination with other approaches," said principal investigator Steven Deeks, professor of medicine at the University of California, San Francisco.
Write to Michael Dabaie at firstname.lastname@example.org
(END) Dow Jones Newswires
March 10, 2020 15:22 ET (19:22 GMT)
© 2020 Dow Jones & Company, Inc.
AAND GILEAD SCIENCES